Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.

被引：0
|
作者：
Grimm, Marc-Oliver
Kesselmeier, Miriam
Leucht, Katharina
Schumacher, Ulrike
Tunger, Antje
Rober, Nadja
Conrad, Karsten
Sommer, Ulrich
Baretton, Gustavo Bruno
Scherag, Andre
Albiges, Laurence
Esteban, Emilio
Barthelemy, Philippe
Schmidinger, Manuela
Busch, Jonas
Perez-Valderrama, Begona
de Velasco, Guillermo
Duran, Ignacio
Schmitz, Marc
Wehner, Rebekka
机构：
[1] Jena Univ Hosp, Dept Urol, Jena, Germany
[2] Jena Univ Hosp, Inst Med Stat Comp & Data Sci, Jena, Germany
[3] Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[4] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Immunol, Dresden, Germany
[5] Univ Hosp Carl Gustav Carus, Inst Pathol, Dresden, Germany
[6] Univ Paris Sud, Gustave Roussy Canc Campus, Dept Canc Med, Villejuif, France
[7] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain
[8] Inst Cancerol Strasbourg Europe, Dept Med Oncol, Strasbourg, France
[9] Med Univ Wien, Vienna Gen Hosp AKH, Dept Internal Med 1, Vienna, Austria
[10] Univ Hosp Charite Berlin, Dept Urol, Berlin, Germany
[11] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
[12] Hosp 12 Octubre, Dept Oncol, Madrid, Spain
[13] Hosp Univ Marques Valdecilla, Dept Med Oncol, Santander, Spain
[14] Tech Univ Dresden, Fac Med Carl Gustav Carus, Dept Immunol, Dresden, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.367
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
367
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial
    Kim, Jwa Hoon
    Ryu, Min-Hee
    Park, Young Soo
    Ma, Jungeun
    Lee, Sun Young
    Kim, Deokhoon
    Kang, Yoon-Koo
    BMC CANCER, 2022, 22 (01)
  • [32] Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial
    Massarelli, Erminia
    William, William
    Johnson, Faye
    Kies, Merrill
    Ferrarotto, Renata
    Guo, Ming
    Feng, Lei
    Lee, J. Jack
    Hai Tran
    Kim, Young Uk
    Haymaker, Cara
    Bernatchez, Chantale
    Curran, Michael
    Barrese, Tomas Zecchini
    Canales, Jaime Rodriguez
    Wistuba, Ignacio
    Li, Lerong
    Wang, Jing
    van der Burg, Sjoerd H.
    Melief, Cornelis J.
    Glisson, Bonnie
    JAMA ONCOLOGY, 2019, 5 (01) : 67 - 73
  • [33] A phase II trial to assess the impact of b2 adrenergic blockade in immune checkpoint inhibitor (ICI)- refractory metastatic triple negative breast cancer (mTNBC)
    Gandhi, Shipra
    Roy, Arya Mariam
    Minderman, Hans
    Rosario, Spencer
    Repasky, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] GOG-3003: IDENTIFYING BIOMARKERS PREDICTIVE OF IMMUNE AND CLINICAL RESPONSE IN A PHASE 2 RCT OF CHEMO-IMMUNOTHERAPY IN RECURRENT OVARIAN CANCER
    Coukos, G.
    Brady, M. F.
    Lankes, H. A.
    Aghajanian, C.
    Gottardo, R.
    Swisher, E. M.
    Kandalaft, L.
    Foukas, P. G.
    Rizack, T.
    Leach, J.
    Salani, R.
    Higgins, R.
    Hanjani, P.
    Morgan, M.
    Edwards, R.
    Bryan, J. K.
    Manjarrez, K. L.
    Mannel, R. S.
    Hershberg, R. M.
    Monk, B. J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 26 - 27
  • [35] Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
    Scherpereel, Arnaud
    Mazieres, Julien
    Greillier, Laurent
    Do, Pascal
    Bylicki, Olivier
    Monnet, Isabelle
    Corre, Romain
    Audigier-Valette, Clarisse
    Locatelli-Sanchez, Myriam
    Molinier, Olivier
    Thiberville, Luc
    Urban, Thierry
    Ligeza-poisson, Catherine
    Planchard, David
    Amour, Elodie
    Morin, Franck
    Moro-Sibilot, Denis
    Zalcman, Gerard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [36] Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
    Scherpereel, Arnaud
    Mazieres, Julien
    Greillier, Laurent
    Do, Pascal
    Bylicki, Olivier
    Monnet, Isabelle
    Corre, Romain
    Audigier-Valette, Clarisse
    Locatelli-Sanchez, Myriam
    Molinier, Olivier
    Thiberville, Luc
    Urban, Thierry
    Ligeza-Poisson, Catherine
    Planchard, David
    Amour, Elodie
    Morin, Franck
    Denis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.
    Loi, Sherene
    Francis, Prudence A.
    Zdenkowski, Nicholas
    Gebski, Val
    Fox, Stephen B.
    White, Michelle
    Kiely, Belinda Emma
    Woodward, Natasha E.
    Hui, Rina
    Redfern, Andrew David
    Calvert, Raewyn
    Rennie, Lauren
    Boyle, Frances M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Patient-reported outcomes (PROs) for tivozanib (TIVO) plus nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.
    Beckermann, Katy
    Choueiri, Toni K.
    Motzer, Robert J.
    Barthelemy, Philippe
    Iacovelli, Roberto
    Emambux, Sheik
    Molina-Cerrillo, Javier
    Garmezy, Benjamin
    Barata, Pedro C.
    Mckay, Rana R.
    Chehrazi-Raffle, Alex
    Hammers, Hans J.
    Heng, Daniel Yick Chin
    Braendle, Edgar E.
    Lebedinsky, Claudia
    Jin, Bo
    Albiges, Laurence
    Mcgregor, Bradley Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [39] Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.
    Harbeck, Nadia
    Nitz, Ulrike
    Christgen, Matthias
    Kates, Ronald E.
    Braun, Michael Wilhelm
    Kummel, Sherko
    Schumacher, Claudia
    Potenberg, Jochem
    Malter, Wolfram
    Augustin, Doris
    Aktas, Bahriye
    Forstbauer, Helmut
    Tio, Joke
    Kleine-Tebbe, Anke
    Liedtke, Cornelia
    de Haas, Sanne
    Deurloo, Regula
    Wuerstlein, Rachel
    Kreipe, Hans Heinrich
    Gluz, Oleg
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
    Wolf, Denise M.
    Yau, Christina
    Campbell, Michael J.
    Glas, Annuska M.
    Mittempergher, Lorenza
    Kuilman, Midas M.
    Barcaru, Andrei
    Swigart, Lamorna Brown
    Nanda, Rita
    Chien, Amy Jo
    Pusztai, Lajos
    Stringer-Reasor, Erica Michelle
    Shatsky, Rebecca Arielle
    Isaacs, Claudine
    Perlmutter, Jane
    DeMichele, Angela
    Yee, Douglas
    Esserman, Laura
    van 't Veer, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345